CD47在淋巴瘤治疗中的研究进展 |
| |
引用本文: | 马瑜晗,桑威,徐开林.CD47在淋巴瘤治疗中的研究进展[J].白血病.淋巴瘤,2021,30(5):314-317. |
| |
作者姓名: | 马瑜晗 桑威 徐开林 |
| |
作者单位: | 徐州医科大学血液病研究所 徐州医科大学附属医院细胞研究和转化医学中心 徐州医科大学附属医院血液科,江苏 徐州 221000 |
| |
摘 要: | CD47作为一种跨膜蛋白,广泛分布于多种细胞,通过与巨噬细胞上信号调节蛋白α(SIRPα)结合,释放抑制信号,逃避巨噬细胞的吞噬。淋巴瘤细胞CD47表达上调是诱导免疫逃逸的重要机制之一,也是潜在的治疗靶点。文章就CD47诱导的免疫逃逸、靶向CD47的单克隆抗体和细胞免疫治疗等治疗手段在淋巴瘤治疗中的研究进展进行综述。
|
关 键 词: | 淋巴瘤 CD47 肿瘤逃逸 免疫逃逸 分子靶向治疗 |
Progress of CD47 in treatment of lymphoma |
| |
Abstract: | As a transmembrane protein, CD47 is widely distributed in a variety of cells. It can bind to signal regulatory protein alpha (SIRPα) on macrophages and release inhibitory signals, thus avoiding phagocytosis of macrophages. In lymphoma cells, the expression of up-regulation of CD47 expression in lymphoma cells is one of the important mechanisms for inducing immune escape, and it is also a potential therapeutic target. This article reviews the research progress of CD47-induced immune escape, monoclonal antibodies targeting CD47 and cellular immunotherapy in the treatment of lymphoma. |
| |
Keywords: | Lymphoma CD47 Tumor escape Immune escape Molecular targeted therapy |
本文献已被 万方数据 等数据库收录! |